Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

FDA-Approved Denosumab Biosimilars Expand Oncology Options in US

Summary by targetedonc.com
Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and cancer-related skeletal issues.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

targetedonc.comtargetedonc.com

FDA-Approved Denosumab Biosimilars Expand Oncology Options in US

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and cancer-related skeletal issues.

Read Full Article
centerforbiosimilars.comcenterforbiosimilars.com

Two More Pairs of Denosumab Biosimilars Enter US Market

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and bone-related metastases.

Read Full Article
curetoday.comcuretoday.com

FDA Approves Stoboclo and Osenvelt as Biosimilars Across Some Cancers

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and cancer-related bone conditions.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

curetoday.com broke the news in on Wednesday, July 9, 2025.
Sources are mostly out of (0)

Similar News Topics

United States icon

United States

News
For You
SearchBlindspotLocal